Responsiveness of different disease activity indices in moderate-to-severe ulcerative colitis.

Date publication

septembre 2024

Journal

Med (New York, N.Y.)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Solitano V, Panaccione R, Sands BE, Wang Z, Hogan M, Zou G, Peyrin-Biroulet L, Danese S, Cornfield LJ, Feagan BG, Singh S, Jairath V, Ma C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39368474

Résumé

Clinical, endoscopic, histological, and composite instruments are currently used to measure disease activity in patients with ulcerative colitis (UC). We compared the responsiveness of the Mayo Clinic score (MCS), modified MCS (mMS; excluding physician global assessment), partial MCS (pMS; MCS without endoscopic subscore), Robart's Histopathology Index (RHI), and UC-100 score to change after ustekinumab treatment in patients with moderately to severely active UC.

Mots clés

Mayo Clinic score, RHI, Translation to patients, UC-100, disease activity index, endoscopy, histology, modified Mayo score, patient-reported outcome, ulcerative colitis

Référence

Med. 2024 09 26;: